ブルトンチロシンキナーゼ阻害剤の心血管安全性:イブルーチニブから次世代剤へ

Luigi Spadafora^1,2, Federico Russo^3,4, Ewelina Bukowska-Olech⁵

¹Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100, Latina, Italy. luigispadafora167@gmail.com.

American journal of cardiovascular drugs : drugs, devices, and other interventions

|August 28, 2025

まとめ

ブルートンチロシンキナーゼ阻害剤 (BTKI) は血液がんの生存率を向上させますが,心血管疾患を引き起こす可能性があります. 新しいBTKIは安全性が高く,治療の選択と患者の結果に役立ちます.

科学分野:

腫瘍学
心臓病科
薬理学について

背景:

ブルートンチロシンキナーゼ (BTK) はB細胞のシグナル伝達に不可欠であり,血液がんの標的である.
BTK阻害剤 (BTKI) はCLLやMCLのような疾患の治療に変化をもたらしました
第一世代のBTKIは,重大な心血管毒性に関連しています.

研究の目的:

BTKIに関連する心血管の毒性を検討する.
第一世代のBTKIと次世代のBTKIの毒性プロフィールを比較する.
BTKIによる心血管疾患の発生率,メカニズム,危険因子,緩和戦略について議論する.

主な方法:

BTKIと心血管毒性に関する既存の文献の記述レビュー.
BTKIの安全性プロファイルに関する臨床証拠の要約
心血管の有害事象のメカニズムと危険因子の分析

主要な成果:

第一世代のBTKI (例えば,イブルチニブ) は心房細動,高血圧,出血と関連しています.
次世代のBTKIは,心血管安全性プロフィールが改善されていることを示しています.
これらの毒性を理解することは,臨床的意思決定に不可欠です.

結論:

BTKIは有効ながん治療法ですが,注意深い心血管のモニタリングが必要です.
リスクの階層化と心臓保護戦略は,安全なBTKIの使用に不可欠です.
予測モデルを洗練し,長期的な患者の安全性を高めるためにさらなる研究が必要です.

さらに関連する動画

12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

関連する概念動画

01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

253

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

253

01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.2K

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

3.2K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

845

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

845

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.1K

01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

223

関連する実験動画